Cargando…

21例原发乳腺淋巴瘤患者疗效及预后分析

OBJECTIVE: To analyze the clinical features, therapeutic methods and prognosis of primary breast lymphoma (PBL). METHODS: Twenty-one PBL patients treated in Ruijin Hospital from January 2003 to December 2013 were included in this study, with 17 diffuse large cell lymphoma (DLBCL), 1 mucosa-associate...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342608/
https://www.ncbi.nlm.nih.gov/pubmed/25916285
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.04.003
_version_ 1783555540308197376
collection PubMed
description OBJECTIVE: To analyze the clinical features, therapeutic methods and prognosis of primary breast lymphoma (PBL). METHODS: Twenty-one PBL patients treated in Ruijin Hospital from January 2003 to December 2013 were included in this study, with 17 diffuse large cell lymphoma (DLBCL), 1 mucosa-associated lymphoid tumor (MALT), 1 follicular lymphoma (FL), 1 Burkitt lymphoma and 1 subcutaneous peniculitis T-cell lymphoma according to the WHO 2008 classification. Of 21 patients, only one patient with MALT has bulged tumor mass (>7 cm), other patients had tumor mass < 5 cm. Six patients had core needle biopsy of tumor, 2 modified radical operation, and others tumor excision for diagnosis. All the patients received chemotherapy. The impacts of surgery, rituximab and prophylaxis with lumbar puncture on the outcomes of patients were analyzed. Survival was estimated using Kaplan-Meier method and compared by log-rank test. All the results were analyzed by SPSS 10.0. RESULTS: Among 21 PBL patients, 19 achieved complete remission (CR), 1 partial remission (PR) and 1 disease progression (PD). Followed-up till July 2014, with median follow-up of 14 months (6–75 months), only one patient died, with 3-year survival of 92.3%. Compared with chemotherapy alone, the progression-free survival (PFS) of combination therapy (surgery plus chemotherapy) was significant longer (P=0.015), but without statistic differences of CR rate and overall survival (OS) between two groups. Among the 20 patients with CD20-positive tumor cells, 17 received Rituximab. PFS and OS, as well as CR rate of PBL had no difference between the treatment with and without Rituximab. The incidence of central nervous system (CNS) infiltration had no difference between patients with and without CNS prophylaxis through lumber-puncture and intrathecal injection. CONCLUSION: With the common subtype of DLBCL, PBL patients had good outcome. Surgery, as a method to obtain tumor samples for diagnosis, could not prolong OS of patients. Therefore, radical operation shouldn't be recommended. PBL was reported to have high risk of CNS events, but prophylaxis with lumber puncture and intrathecal injection couldn't decrease the incidence of CNS infiltration.
format Online
Article
Text
id pubmed-7342608
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73426082020-07-16 21例原发乳腺淋巴瘤患者疗效及预后分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To analyze the clinical features, therapeutic methods and prognosis of primary breast lymphoma (PBL). METHODS: Twenty-one PBL patients treated in Ruijin Hospital from January 2003 to December 2013 were included in this study, with 17 diffuse large cell lymphoma (DLBCL), 1 mucosa-associated lymphoid tumor (MALT), 1 follicular lymphoma (FL), 1 Burkitt lymphoma and 1 subcutaneous peniculitis T-cell lymphoma according to the WHO 2008 classification. Of 21 patients, only one patient with MALT has bulged tumor mass (>7 cm), other patients had tumor mass < 5 cm. Six patients had core needle biopsy of tumor, 2 modified radical operation, and others tumor excision for diagnosis. All the patients received chemotherapy. The impacts of surgery, rituximab and prophylaxis with lumbar puncture on the outcomes of patients were analyzed. Survival was estimated using Kaplan-Meier method and compared by log-rank test. All the results were analyzed by SPSS 10.0. RESULTS: Among 21 PBL patients, 19 achieved complete remission (CR), 1 partial remission (PR) and 1 disease progression (PD). Followed-up till July 2014, with median follow-up of 14 months (6–75 months), only one patient died, with 3-year survival of 92.3%. Compared with chemotherapy alone, the progression-free survival (PFS) of combination therapy (surgery plus chemotherapy) was significant longer (P=0.015), but without statistic differences of CR rate and overall survival (OS) between two groups. Among the 20 patients with CD20-positive tumor cells, 17 received Rituximab. PFS and OS, as well as CR rate of PBL had no difference between the treatment with and without Rituximab. The incidence of central nervous system (CNS) infiltration had no difference between patients with and without CNS prophylaxis through lumber-puncture and intrathecal injection. CONCLUSION: With the common subtype of DLBCL, PBL patients had good outcome. Surgery, as a method to obtain tumor samples for diagnosis, could not prolong OS of patients. Therefore, radical operation shouldn't be recommended. PBL was reported to have high risk of CNS events, but prophylaxis with lumber puncture and intrathecal injection couldn't decrease the incidence of CNS infiltration. Editorial office of Chinese Journal of Hematology 2015-04 /pmc/articles/PMC7342608/ /pubmed/25916285 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.04.003 Text en 2015年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
21例原发乳腺淋巴瘤患者疗效及预后分析
title 21例原发乳腺淋巴瘤患者疗效及预后分析
title_full 21例原发乳腺淋巴瘤患者疗效及预后分析
title_fullStr 21例原发乳腺淋巴瘤患者疗效及预后分析
title_full_unstemmed 21例原发乳腺淋巴瘤患者疗效及预后分析
title_short 21例原发乳腺淋巴瘤患者疗效及预后分析
title_sort 21例原发乳腺淋巴瘤患者疗效及预后分析
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342608/
https://www.ncbi.nlm.nih.gov/pubmed/25916285
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2015.04.003
work_keys_str_mv AT 21lìyuánfārǔxiànlínbāliúhuànzhěliáoxiàojíyùhòufēnxī
AT 21lìyuánfārǔxiànlínbāliúhuànzhěliáoxiàojíyùhòufēnxī
AT 21lìyuánfārǔxiànlínbāliúhuànzhěliáoxiàojíyùhòufēnxī
AT 21lìyuánfārǔxiànlínbāliúhuànzhěliáoxiàojíyùhòufēnxī
AT 21lìyuánfārǔxiànlínbāliúhuànzhěliáoxiàojíyùhòufēnxī